Literature DB >> 19805346

A progenitor cell origin of myeloid malignancies.

Hiroshi Haeno1, Ross L Levine, D Gary Gilliland, Franziska Michor.   

Abstract

All cancers rely on cells that have properties of long-term self-renewal or "stemness" to maintain and propagate the tumor, but the cell of origin of most cancers is still unknown. Here, we design a stochastic mathematical model of hematopoietic stem and progenitor cells to study the evolutionary dynamics of cancer initiation. We consider different evolutionary pathways leading to cancer-initiating cells in JAK2V617F-positive myeloproliferative neoplasms (MPN): (i) the JAK2V617F mutation may arise in a stem cell; (ii) a progenitor cell may first acquire a mutation conferring self-renewal, followed by acquisition of the JAK2V617F mutation; (iii) the JAK2V617F mutation may first emerge in a progenitor cell, followed by a mutation conferring self-renewal; and (iv) a mutation conferring self-renewal to progenitors may arise in the stem cell population without causing a change in the stem cell's phenotype, followed by the JAK2V617F mutation emerging in a progenitor cell. We find mathematical evidence that a progenitor is the most likely cell of origin of JAK2V617F-mutant MPN. These results may also have relevance to other tumor types arising in tissues that are organized as a differentiation hierarchy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805346      PMCID: PMC2757818          DOI: 10.1073/pnas.0908107106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

3.  The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.

Authors:  E Sitnicka; N Lin; G V Priestley; N Fox; V C Broudy; N S Wolf; K Kaushansky
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

4.  Imaging hematopoietic precursor division in real time.

Authors:  Mingfu Wu; Hyog Young Kwon; Frederique Rattis; Jordan Blum; Chen Zhao; Rina Ashkenazi; Trachette L Jackson; Nicholas Gaiano; Tim Oliver; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

Review 7.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

8.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

9.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

10.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

View more
  23 in total

1.  TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.

Authors:  Elise Bonvin; Enrico Radaelli; Martin Bizet; Flavie Luciani; Emilie Calonne; Pascale Putmans; David Nittner; Nitesh Kumar Singh; Sara Francesca Santagostino; Valérie Petit; Lionel Larue; Jean Christophe Marine; François Fuks
Journal:  Cancer Res       Date:  2018-12-11       Impact factor: 12.701

2.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Authors:  Kelly Moran-Crusio; Linsey Reavie; Alan Shih; Omar Abdel-Wahab; Delphine Ndiaye-Lobry; Camille Lobry; Maria E Figueroa; Aparna Vasanthakumar; Jay Patel; Xinyang Zhao; Fabiana Perna; Suveg Pandey; Jozef Madzo; Chunxiao Song; Qing Dai; Chuan He; Sherif Ibrahim; Miloslav Beran; Jiri Zavadil; Stephen D Nimer; Ari Melnick; Lucy A Godley; Iannis Aifantis; Ross L Levine
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

3.  Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.

Authors:  Jie Zhang; Angela G Fleischman; Dominik Wodarz; Natalia L Komarova
Journal:  J Theor Biol       Date:  2017-05-10       Impact factor: 2.691

4.  Stochastic tunneling and metastable states during the somatic evolution of cancer.

Authors:  Peter Ashcroft; Franziska Michor; Tobias Galla
Journal:  Genetics       Date:  2015-01-26       Impact factor: 4.562

Review 5.  The evolution of metapopulation dynamics and the number of stem cells in intestinal crypts and other tissue structures in multicellular bodies.

Authors:  David Birtwell; Georg Luebeck; Carlo C Maley
Journal:  Evol Appl       Date:  2020-08-12       Impact factor: 5.183

Review 6.  What does physics have to do with cancer?

Authors:  Franziska Michor; Jan Liphardt; Mauro Ferrari; Jonathan Widom
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

7.  Stochastic dynamics of cancer initiation.

Authors:  Jasmine Foo; Kevin Leder; Franziska Michor
Journal:  Phys Biol       Date:  2011-02-07       Impact factor: 2.583

Review 8.  Why doesn't imatinib cure chronic myeloid leukemia?

Authors:  Robert L Redner
Journal:  Oncologist       Date:  2010-02-02

Review 9.  The mathematics of cancer: integrating quantitative models.

Authors:  Philipp M Altrock; Lin L Liu; Franziska Michor
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

Review 10.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.